Intervention Protocol

You have free access to this content

Interventions for reducing inflammation in familial Mediterranean fever

  1. Bin Wu1,
  2. Ting Xu1,
  3. Youping Li2,*,
  4. Xi Yin1

Editorial Group: Cochrane Cystic Fibrosis and Genetic Disorders Group

Published Online: 6 JAN 2014

Assessed as up-to-date: 18 DEC 2013

DOI: 10.1002/14651858.CD010893


How to Cite

Wu B, Xu T, Li Y, Yin X. Interventions for reducing inflammation in familial Mediterranean fever (Protocol). Cochrane Database of Systematic Reviews 2014, Issue 1. Art. No.: CD010893. DOI: 10.1002/14651858.CD010893.

Author Information

  1. 1

    West China Hospital, Sichuan University, Department of Pharmacy, Chengdu, Sichuan, China

  2. 2

    West China Hospital, Sichuan University, Chinese Cochrane Centre, Chinese Evidence-Based Medicine Centre, Chengdu, Sichuan, China

*Youping Li, Chinese Cochrane Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, Sichuan, 610041, China. yzmylab@hotmail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 6 JAN 2014

SEARCH

References

Additional references

Alpay 2012
  • Alpay N,  Sumnu A,  Calışkan Y,  Yazıcı H,  Türkmen A,  Gül A. Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever. Rheumatology International 2012;32(10):3277-9.
Balci 2002
  • Balci B, Tinaztepe K, Yilmaz E, Guçer S, Ozen S, Topaloğlu R, et al. MEFV gene mutations in familial Mediterranean fever phenotype II patients with renal amyloidosis in childhood: a retrospective clinicopathological and molecular study. Nephrology Dialysis Transplantation 2002;17(11):1921-3.
Baykal 2003
  • Baykal Y,  Saglam K,  Yilmaz MI,  Taslipinar A,  Akinci SB,  Inal A. Serum sIL-2r, IL-6, IL-10 and TNF-alpha level in familial Mediterranean fever patients. Clinical Rheumatology 2003;22(2):99-101.
Ben-Chetrit 2006
  • Ben-Chetrit E,  Bergmann S,  Sood R. Mechanism of the anti-inflammatory effect of colchicine in rheumatic diseases: a possible new outlook through microarray analysis. Rheumatology (Oxford) 2006;45(3):274-82.
Bilgen 2011
  • Bilgen SA,  Kilic L,  Akdogan A,  Kiraz S,  Kalyoncu U,  Karadag O, et al. Effects of anti-tumor necrosis factor agents for familial mediterranean fever patients with chronic arthritis and/or sacroiliitis who were resistant to colchicine treatment. Journal of Clinical Rheumatology 2011;17(7):358-62.
Centola 2000
  • Centola M,  Wood G,  Frucht DM,  Galon J,  Aringer M,  Farrell C,  et al. The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood 2000;95(10):3223-31.
Cerquaglia 2005
  • Cerquaglia C,  Diaco M,  Nucera G,  La Regina M,  Montalto M,  Manna R. Pharmacological and clinical basis of treatment of Familial Mediterranean Fever (FMF) with colchicine or analogues: an update. Current Drug Targets. Inflammation and Allergy 2005;4(1):117-24.
Chae 2008
  • Chae JJ, Wood G, Richard K, Jaffe H, Colburn NT, Masters SL, et al. The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-kappaB through its N-terminal fragment. Blood 2008;112(5):1794-803.
Chae 2009
  • Chae JJ,  Aksentijevich I,  Kastner DL. Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy. British Journal of Haematology 2009;146(5):467-78.
Cronstein 2006
Deeks 2011
  • Deeks JJ, Higgins JPT, Altman DG on behalf of the Cochrane Statistical Methods Group (editors). Chapter 9: Analysing data and undertaking meta-analysis. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Economides 2003
  • Economides AN,  Carpenter LR,  Rudge JS,  Wong V,  Koehler-Stec EM,  Hartnett C,  et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nature Medicine 2003;9(1):47-52.
Elbourne 2002
  • Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
Endnote X6
  • Thomson Reuters. Endnote X6. 6.0. San Francisco: Thomson Reuters, 2012.
French FMF Consortium 1997
  • French FMF Consortium. A candidate gene for familial Mediterranean fever. Nature Genetics 1997;17(1):25-31.
Goldfinger 1972
  • Goldfinger SE. Colchicine for familial Mediterranean fever. The New England Journal of Medicine 1972;287(25):1302.
Hashkes 2012
  • Hashkes PJ,  Spalding SJ,  Giannini EH,  Huang B,  Johnson A,  Park G,  et al. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Annals of Internal Medicine 2012;157(8):533-41.
Higgins 2011a
  • Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Higgins 2011b
  • Higgins JPT, Altman DG, Sterne JAC, on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Higgins 2011c
  • Higgins JPT, Deeks JJ, Altman DG on behalf of the Cochrane Statistical Methods Group (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Higgins 2011d
  • Higgins JPT, Altman DG, Sterne JAC on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Kiraz 1998
  • Kiraz S,  Ertenli I,  Arici M,  Calgüneri M,  Haznedaroglu I,  Celik I, et al. Effects of colchicine on inflammatory cytokines and selectins in familial Mediterranean fever. Clinical and Experimental Rheumatology 1998;16(6):721-4.
Konstantopoulos 2003
  • Konstantopoulos K,  Kanta A,  Deltas C,  Atamian V,  Mavrogianni D,  Tzioufas AG,  et al. Familial Mediterranean fever associated pyrin mutations in Greece. Annals of the Rheumatic Diseases 2003;62(5):479-81.
Koné-Paut 2011
La Regina 2003
  • La Regina M,  Nucera G,  Diaco M,  Procopio A,  Gasbarrini G,  Notarnicola C, et al. Familial Mediterranean fever is no longer a rare disease in Italy. European Journal of Human Genetics 2003;11(1):50-6.
Lidar 2006
  • Lidar M, Yaqubov M, Zaks N, Ben-Horin S, Langevitz P, Livneh A. The prodrome: a prominent yet overlooked pre-attack manifestation of familial Mediterranean fever. Journal of Rheumatology 2006;33(6):1089-92.
Livneh 1997
Livneh 2006
  • Livneh A. Amyloidosis of familial Mediterranean fever (FMF)--insights to FMF phenotype II. Harefuah 2006;145(10):743-5, 782.
Mansfield 2001
  • Mansfield E,  Chae JJ,  Komarow HD,  Brotz TM,  Frucht DM,  Aksentijevich I,  et al. The familial Mediterranean fever protein, pyrin, associates with microtubules and colocalizes with actin filaments. Blood 2001;98(3):851-9.
Melikoğlu 2000
  • Melikoğlu M, Ozdoğan H, Korkmaz C, Kasapçopur O, Arisoy N, Akkuş S, et al. A survey of phenotype II in familial Mediterranean fever. Annals of the Rheumatic Diseases 2000;59(11):910-3.
Migita 2012
  • Migita K,  Uehara R,  Nakamura Y,  Yasunami M,  Tsuchiya-Suzuki A,  Yazaki M, et al. Familial Mediterranean fever in Japan. Medicine (Baltimore) 2012;91(6):337-43.
Ozen 2011
  • Ozen S,  Bilginer Y,  Aktay Ayaz N,  Calguneri M. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. Journal of Rheumatology 2011;38(3):516-8.
Papin 2007
  • Papin S, Cuenin S, Agostini L, Martinon F, Werner S, Beer HD, et al. The SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1beta processing. cell death and differentiation 2007;14(8):1457-66.
Park 2012
Review Manager (RevMan) 2012
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Sampaio 1991
  • Sampaio EP,  Sarno EN,  Galilly R,  Cohn ZA,  Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. Journal of Experimental Medicine 1991;173(3):699-703.
Seyahi 2006
  • Seyahi E,  Ozdogan H,  Celik S,  Ugurlu S,  Yazici H. Treatment options in colchicine resistant familial Mediterranean fever patients: thalidomide and etanercept as adjunctive agents. Clinical and Experimental Rheumatology 2006;24(5 Suppl 42):S99-103.
Shohat 2011
Soriano 2012
Sterne 2011
  • Sterne JAC, Egger M, Moher D on behalf of the Cochrane Bias Methods Group. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Terkeltaub 2009
Terkeltaub 2013
  • Terkeltaub RA, Schumacher HR, Carter JD, Baraf HS, Evans RR, Wang J,  et al. Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator. Arthritis Research and Therapy 2013;15(1):R15.
The International FMF Consortium 1997
  • The International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 1997;90(4):797-807.
Tweezer-Zaks 2008
  • Tweezer-Zaks N,  Rabinovich E,  Lidar M,  Livneh A. Interferon-alpha as a treatment modality for colchicine- resistant familial Mediterranean fever. Journal of Rheumatology 2008;35(7):1362-5.
WHO 2013
  • WHO. 19th Expert Committee: Expert reviews. www.who.int/selection_medicines/committees/expert/19/reviews/en/index.html (accessed 13 June 2013).
Yalçinkaya 2009
  • Yalçinkaya F, Ozen S, Ozçakar ZB, Aktay N, Cakar N, Düzova A, et al. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford) 2009;48(4):395-8.
Özçakar 2012
  • Özçakar ZB,  Yüksel S,  Ekim M,  Yalçınkaya F. Infliximab therapy for familial Mediterranean fever-related amyloidosis: case series with long term follow-up. Clinical Rheumatology 2012;31(8):1267-71.